Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2022 Jan;15(1):255-266.
doi: 10.1111/cts.13145. Epub 2021 Nov 7.

A randomized, multicenter trial assessing the effects of rapastinel compared to ketamine, alprazolam, and placebo on simulated driving performance

Affiliations
Randomized Controlled Trial

A randomized, multicenter trial assessing the effects of rapastinel compared to ketamine, alprazolam, and placebo on simulated driving performance

Shengfang Su et al. Clin Transl Sci. 2022 Jan.

Abstract

N-methyl-D-aspartate ionotropic glutamatergic receptor (NMDAR) modulators, including rapastinel and ketamine, elicit rapid and sustained antidepressant responses in patients with treatment-resistant major depressive disorder. This phase I, randomized, multicenter, placebo-controlled, five-period, crossover, single-dose study evaluated simulated driving performance of healthy participants (N = 107) after single doses of rapastinel slow intravenous (i.v.) bolus 900 and 1800 mg, alprazolam oral 0.75 mg (positive control), ketamine i.v. infusion 0.5 mg/kg (clinical comparator), and placebo ~ 45 min before driving. The primary end point was SD of lateral position (SDLP) during the 60-min 100-km simulated driving scenario. Additional measures of driving performance, sleepiness, and cognition were also evaluated. To assess effects over time, mean SDLP was calculated for each 10-min interval of driving. Sensitivity of the assays was confirmed with alprazolam (all placebo comparisons p < 0.02). Rapastinel 900 and 1800 mg did not significantly affect simulated driving performance compared to placebo (both p > 0.5). Both rapastinel doses resulted in significantly less impaired driving compared to alprazolam or ketamine (all p < 0.002); ketamine significantly impaired driving compared to placebo (p = 0.0001). Results for the additional measures were similar to the primary end point. No new safety signals were observed for any study interventions. This first study of rapastinel effects on simulated driving found that rapastinel 900 and 1800 mg did not impair driving performance, but ketamine 0.5 mg/kg resulted in significantly impaired driving performance. Ketamine's effects on driving were maintained for at least 105 min, indicating that clinicians should be vigilant to prevent or postpone driving in patients after ketamine treatment.

Trial registration: ClinicalTrials.gov NCT03814733.

PubMed Disclaimer

Conflict of interest statement

R.B. is a full‐time employee at AbbVie, Inc. (previously Allergan plc). S.S., J.R., C.S., and A.P. are former full‐time employees at AbbVie, Inc. (previously Allergan plc). T.H. (Chief Executive Officer, Owner) and G.K. (President, Chief Scientific Officer, Owner) of Cognitive Research Corporation and G.K. (Author, Owner) of CogScreen.

Similar articles

Cited by

References

    1. Friedrich MJ. Depression is the leading cause of disability around the world. JAMA. 2017;317:1517. - PubMed
    1. Hasin DS, Sarvet AL, Meyers JL, et al. Epidemiology of adult DSM‐5 major depressive disorder and its specifiers in the United States. JAMA Psychiatry. 2018;75:336‐346. - PMC - PubMed
    1. Greenberg PE, Fournier AA, Sisitsky T, Pike CT, Kessler RC. The economic burden of adults with major depressive disorder in the United States (2005 and 2010). J Clin Psychiatry. 2015;76:155‐162. - PubMed
    1. Warden D, Rush AJ, Trivedi MH, Fava M, Wisniewski SR. The STAR*D Project results: a comprehensive review of findings. Cur Psychiatr Rep. 2007;9:449‐459. - PubMed
    1. IsHak WW, Mirocha J, James D, et al. Quality of life in major depressive disorder before/after multiple steps of treatment and one‐year follow‐up. Acta Psychiatr Scand. 2015;131:51‐60. - PMC - PubMed

Publication types

Associated data

Grants and funding